Key Takeaways
Extended Takeaways
- In this open-label pilot, all 10 participants met HAMD response criteria by H72, 60% achieved response by H24, and 80% achieved remission by H48, with remission sustained at D30 for all 9 subjects who remitted during treatment.
- Clinical improvement often emerged before the highest brexanolone dose was reached: the infusion used 30 µg/kg/hour (Hours 0–4), 60 µg/kg/hour (Hours 4–24), and 90 µg/kg/hour (Hours 24–52), yet many participants responded before Hour 24.
- Anxiety improved markedly alongside depressive symptoms, with STAI-S showing mean difference=−26.9, P<.001 by H72 and mean difference=−28.8, P<.001 by D30; STAI-T also fell substantially, suggesting this 'trait' measure was strongly state dependent in acute PPD recovery.
- Potentially relapse-relevant residual symptoms also shifted quickly: SHAPS score decreased by 89% from 6.2 (±3.7) to 0.7 (±1.1), mean difference= −5.5, P < .001, while RRS decreased by 29% from 28.4 (±2.5) to 20.3 (±8.3), mean difference= −8.1, P = .008.
- Maternal functioning improved within 12 hours after infusion completion, with BIMF increasing 56% from 58.5 (±9.2) to 91.3 (±16.8), mean difference = 32.8, P < .001, and rising further to 101.2 at D30.
- Interpret these findings cautiously in practice because the sample was small (N=10), homogeneous, and treated in an inpatient, single-arm setting while continuing existing psychotropics, so the study describes temporal patterns of change rather than brexanolone-specific causal effects.
